Navigation Links
Cephalon in Medical News

Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. F...

inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.

SOMERSET, N.J., March 6 /PRNewswire-FirstCall/ -- inVentiv Selling Solutions, a division of inVentiv Health (Nasdaq: VTIV ) and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has signed a contract with Cephalon Inc. to provide a sales tea...

Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs

NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory an...

Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon

Unique off-label marketing case results in $425M settlement WASHINGTON, Sept. 29 /PRNewswire/ -- The government's investigation into Cephalon Inc.'s illegal marketing practices that culminated in today's $425,000,000 settlement and guilty plea by the pharmaceutical company began in Janua...

Provigil Patent Extension Accorded To Cephalon

Cephalon has been accorded a further six months of patent extension by the FDA for its pediatric sleep disorder treatment medication//, Provigil. Cephlaon had complied with the terms of an explicit written request that entailed the provision of clinical studies data after studying the effect...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...otic catastrophe (a non-apoptotic pathway). cephalon holds exclusive rights to market and develop TREAN...ber of the Fortune 1000 and the S&P 500 Index, cephalon currently employs approximately 3,000 people in th...Utah, and suburban Minneapolis, Minnesota. cephalon has a growing presence in Europe, the Middle East ...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...Praecis Pharmaceuticals II-54 Biotest Acquires ImmunoGen Anticancer Technology Rights II-54 Hana Signs Licensing Agreement with Inex II-54 cephalon Acquires Zeneus II-54 5. Focus on Select Players II-55 Amgen Inc (USA) II-55 Avalon Pharmaceuticals, Inc. (USA) II-55 Bristol-Myers S...

NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies

...t Cephalon. "Based on the findings of this study, cephalon will submit a supplemental New Drug Application to...ber of the Fortune 1000 and the S&P 500 Index, cephalon currently employs approximately 3,000 people in th..., Utah, and suburban Minneapolis, Minnesota. cephalon has a growing presence in Europe, the Middle East ...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

...He is the chief executive officer and chairman of the board of directors of cephalon Inc., an international biopharmaceutical company in Chester County, Pennsylvania. Dr. Baldino founded cephalon in 1987 and has served as chief executive officer and director since its in...

Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy

...lso known as shift work disorder, and narcolepsy. cephalon has finalized the commercialization plans for NUVI...s Programs As part of the launch of NUVIGIL, cephalon is introducing several new programs designed to ex...st insured patients with co-pay costs for NUVIGIL, cephalon will offer the NUVIGIL Prescription Savings Progra...
Cephalon in Medical Technology

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

Study Reports 92 Percent Response Rate to Combination Treatment FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-c...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

...ber of the Fortune 1000 and the S&P 500 Index, cephalon currently employs approximately 3,000 people in th..., Utah, and suburban Minneapolis, Minnesota. cephalon has a growing presence in Europe, the Middle East and Africa. The cephalon European headquarters and pre-clinical development...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...reatment options," said Frank Baldino, Jr., Ph.D., cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like cephalon to make that investment and take that risk if we a...he overall cost of healthcare." Developed by cephalon scientists, lestaurtinib is a potent inhibitor of ...

Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder

...ift work, time zone changes and medications. cephalon is preparing to launch NUVIGIL, the longer-lasting...ber of the Fortune 1000 and the S&P 500 Index, cephalon currently employs approximately 3,000 people in th..., Utah, and suburban Minneapolis, Minnesota. cephalon has a growing presence in Europe, the Middle East ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression

...bo group included restlessness and anxiety. cephalon is preparing to launch NUVIGIL, the longer-lasting...ber of the Fortune 1000 and the S&P 500 Index, cephalon currently employs approximately 3,000 people in th..., Utah, and suburban Minneapolis, Minnesota. cephalon has a growing presence in Europe, the Middle East ...

Cephalon Signs Option Agreement to Acquire Ception Therapeutics

...t the companies have signed an agreement providing cephalon with an option to purchase all outstanding capital...Ception. Under the terms of the option agreement, cephalon will pay Ception a $100 million upfront option pay...TNF (tumor necrosis factor) receptor agents. cephalon may exercise its option at any time prior to expir...

Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain

...hrough pain. In its letter, the FDA requested that cephalon implement and demonstrate the effectiveness of pro.../www.fentora.com ). The FENTORA sNDA, submitted by cephalon in November 2007, is based on data from three rand...ll as more specific risks and uncertainties facing cephalon such as those set forth in its reports on Form 8-K...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...nical endpoints and/or data analysis. In addition, cephalon has completed a phase 2 study with TREANDA in comb...tients with relapsed indolent and mantle cell NHL. cephalon plans to submit a new drug application (NDA) for T...ing treatment with rituximab. In September 2007, cephalon submitted an NDA requesting approval of TREANDA fo...

TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil

...TREANDA for the treatment of patients with CLL and cephalon expects a review decision from FDA by the end of M...REANDA for CLL in August 2007, which would entitle cephalon to a seven-year period of marketing exclusivity fo...tients with relapsed indolent and mantle cell NHL. cephalon plans to submit an NDA for TREANDA by the end of 2...

Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma

... a New Drug Application (NDA). In September 2007, cephalon submitted an NDA requesting approval of TREANDA fo...ay be attributable to its unique chemical design. cephalon holds exclusive rights to market and develop TREAN... HCl in Japan and selected Asian countries. About cephalon Oncology ...
Cephalon in Biological News

Researchers seek to design first treatment for neuroAIDS

...dical Center, had served as an auditor of Cephalon's PRECEPT trial, where CEP-1347 was tested as a treatment for Parkinson's disease. He proposed that cephalon make the drug available for the study of the drug's effect on neuroAIDs. CEP-1347 has already proven capable of reversing the neurotoxic effects of HI...
Cephalon in Biological Technology

$425 Million Cephalon Civil Settlement and Criminal Fine; In America's Largest

Biotechnology Medicaid Fraud Case; Qui Tam Whistleblower Attorney Brian P. Kenney, Esq. Filed First Complaint With Client's Off-Label Marketing Allegations In 2003; Additional Complaints Were Filed; $375 Million Civil Settlement, $50 Million Corporate Criminal Fine Today PHILADELPHIA,...

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

...n/prnh/20090731/PH54744 ) "Since joining cephalon two years ago, Craig has clearly demonstrated an a... and vision will support the dynamic growth of the cephalon Oncology business and allow us to continue to brin...patients battling cancer." Phillips joined cephalon in 2007 as Senior Group Director of Sales, Nationa...

Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings

...% convertible senior subordinated notes due 2014. cephalon has also granted the underwriters a 30-day option,...rincipal amount plus accrued and unpaid interest. cephalon may not redeem the notes prior to the maturity dat...e additional notes or shares of common stock. cephalon intends to use a portion of the net proceeds of th...

Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes

...due 2014 through two concurrent public offerings. cephalon will grant the underwriters a 30-day option, solel...of pricing of the offering by negotiations between cephalon and the underwriters. The notes will be subordina... upon the consummation of the other offering. cephalon intends to use a portion of the net proceeds of th...

Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR

...'s Trade Alerts include: Forest Laboratories Inc. (NYSE: FRX ), Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ), Allergan Inc. (NYSE: AGN ), cephalon Inc. (Nasdaq: CEPH ), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX ) and Adolor Corp. (Nasdaq: ADLR ). Join the fastest growing investment c...

Cephalon's New Product Launches Pace Record 2008 Sales

...elves coupled with our internal pipeline positions cephalon favorably for future growth." The company i...e per common share guidance of $6.50 - $6.60. cephalon is introducing first quarter 2009 sales guidance o...ors for one week after the call. About cephalon , Inc. Founded in 1987, Cephalon, Inc. is a...

Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS

... this role, Dr. Duddu will lead all aspects of the cephalon drug delivery business at CIMA, its wholly owned d...In his new role, Dr. Duddu will be a member of the cephalon Technical Operations leadership team and will repo..., OraVescent(R), and OTC(R) (oral transmuscosal). cephalon currently manufactures the following products in t...

Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor

...interim results of the ImmuPharma Phase IIb study. cephalon will assume all expenses for Phase III studies, re... of the deal last year. In exercising its option, cephalon will pay ImmuPharma a one-time license fee of $30 ...y diseases." "The exercise of the option by cephalon validates the analysis ImmuPharma made of the inte...

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals

...X until 2025 and we intend to work diligently with cephalon to protect this important product," said Manya S. ...oprietary drug delivery formulation technologies. cephalon is the exclusive licensee and marketer of AMRIX in...urrent with the patent protection described above, cephalon has a three-year period of marketing exclusivity p...

Standard & Poor's Announces Changes to U.S. Indices

...th in the index. -- S&P MidCap 400 constituent cephalon Inc. (Nasdaq: CEPH ) will be added to the S&...Mariner Energy Inc. (NYSE: ME ) will replace cephalon Inc. in the S&P MidCap 400, after the close of trading on Friday, November 14. cephalon is taking the place of General Growth Propert...
Cephalon in Biological Definition

Biotechnology

...gy companies, ranked by 2003 sales, are: Amgen Genentech Serono Biogen Idec Chiron Genzyme MedImmune Gilead Sciences cephalon Millennium Pharmaceuticals Biotechnology in fiction Star Trek The Breen use starships with organic technology. The starship US...
Cephalon in Biological Dictionary

Sutures

...ct the bones of the skull. ... Feeling the cranial sutures and fontanelles is ... The facial sutures of Asaphiscus run from the anterior of the cephalon to the ... What are facial sutures ? ... Facial sutures once played a primary role in ... Sutures , or stitches, are the most commonly used met...
Other Tags
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) is ... and safe practice for patients with rheumatic diseases. , ... infusions are administered in an infusion center, provider’s office, ... nurse (RN), as defined in their State Nurse Practice ... receiving these medications during a first infusion, as well ...
(Date:3/3/2015)... Dr. Michael Nochomovitz has ... clinical integration and network development officer for ... established role, Dr. Nochomovitz is responsible for ... physician enterprise, its integration within NewYork-Presbyterian and ... Physicians. , Dr. Nochomovitz brings 17 years ...
(Date:3/3/2015)... NY (PRWEB) March 03, 2015 Topical BioMedics, ... as a webinar streamed live on Tuesday, March 10th, 12pm ... will be archived and accessible 24/7. , ... public. The topic for the March 10th workshop is “Opioid ... discussion, considering that the U.S. represents 5% of the world’s ...
(Date:3/3/2015)... March 03, 2015 The number of ... 1984 to about 15%. This increases to 50% by ... T, Cook JL, Yuzpe AA, et al. Estimating the ... 738-46). Dr. Jason Hitkari, a reproductive endocrinologist and co-director ... of TCM and clinical director and founder of Acubalance ...
(Date:3/3/2015)... Introducing 3D Digital Technologies to their state-of-the-art facilities, ... Digital Dentistry. Acute precision in 3D Digital ... no room for error during the manufacturing process. ... to significantly reduce “chair time” and cut material ... reducing labor and material costs proving to be ...
Breaking Medicine News(10 mins):Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Dr. Michael Nochomovitz to Lead Clinical Integration and Network Development for the NewYork-Presbyterian Healthcare System 2Health News:Dr. Michael Nochomovitz to Lead Clinical Integration and Network Development for the NewYork-Presbyterian Healthcare System 3Health News:Dr. Michael Nochomovitz to Lead Clinical Integration and Network Development for the NewYork-Presbyterian Healthcare System 4Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 2Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 3
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
Other Contents